BioCatalystWatch
IMTXWorkspace / IMTX / OverviewCompany library
Price
Market cap
Next catalystExpected 2H 2026IMA203CD8 — adult PRAME-positive solid-tumor trial · Phase 1 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

IMA402

PRAME × TCR/CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

IMA401/IMA402

MAGEA4/8 × PRAME

PreINDP1P2P3FilingApproved
Upcoming / outlook

IMA203CD8

PRAME (HLA-A*02:01)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Anzu-cel (IMA203)

PRAME (HLA-A*02:01)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

IMA203CD8

PRAME (HLA-A*02:01)

PreINDP1P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

IMA402

PRAME × TCR/CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

IMA203CD8

PRAME (HLA-A*02:01)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Anzu-cel (IMA203)

PRAME (HLA-A*02:01)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

IMA203CD8

PRAME (HLA-A*02:01)

PreINDP1P3FilingApproved
Upcoming / outlook

IMA401/IMA402

MAGEA4/8 × PRAME

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

IMA203CD8

PRAME (HLA-A*02:01)

Anzu-cel (IMA203)

PRAME (HLA-A*02:01)

PreINDP1P2P3FilingApproved

Anzu-cel (IMA203)

PRAME (HLA-A*02:01)

PreINDP1P2P3FilingApproved
Anzu-cel (IMA203)

PRAME (HLA-A*02:01)

PreINDP1P2P3FilingApproved
IMA203CD8

PRAME (HLA-A*02:01)

PreINDP1P2P3FilingApproved
IMA203CD8

PRAME (HLA-A*02:01)

PreINDP1P2P3FilingApproved
IMA301

Cancer-testis antigen (unspecified)

PreINDP1P2P3FilingApproved

History / paused

COL6A3 × Patient-specific pHLA targets

PreINDP1P2P3FilingApproved

COL6A3 × Patient-specific pHLA targets

PreINDP1P2P3FilingApproved

COL6A3 × Patient-specific pHLA targets

PreINDP1P2P3FilingApproved

COL6A3 × Patient-specific pHLA targets

PreINDP1P2P3FilingApproved

COL6A3 × Patient-specific pHLA targets

PreINDP1P2P3FilingApproved

MAGEA4/A8

PreINDP1P2P3FilingApproved

MAGEA4/A8

PreINDP1P2P3FilingApproved

MAGEA1

PreINDP1P2P3FilingApproved

MAGEA1

PreINDP1P2P3FilingApproved

COL6A3 exon 6 (HLA-A*02)

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

IMTX SEC archive